Dietary Supplement Recalled: Douglas Labs Stress-B-Plus Due to Niacin Form Mismatch
Nestle Health Science is recalling Douglas Labs Stress-B-Plus Dietary Supplement due to incorrect formulation. The product contains Niacin as Nicotinic acid but the label states Niacinamide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is a formulation and labeling discrepancy (niacin form mismatch) rather than a high-risk contaminant, warranting Moderate severity per the rubric for labeling errors without reported harm.
Plain-English summary
Douglas Labs Stress-B-Plus Dietary Supplement Tablets are being recalled by Nestle Health Science due to an incorrect formulation. The product was manufactured with Niacin as Nicotinic acid, but the supplement facts panel on the label states it contains Niacin as Niacinamide.
The affected products are identified by Lot Numbers 50335944 and 50344396, with an expiration date of April 11, 2026 (UPC #10539 97452). Approximately 3,269 bottles have been distributed to 36 states.
The formulation discrepancy means the product does not match what is represented on the label. Consumers who have purchased affected lots are advised to discontinue use and contact their retailer for guidance.
The recalled product
- Product
- Douglas Labs Stress-B-Plus Dietary Supplement, Tablets, 90 tablets per bottle. UPC # 10539 97452, Lot Numbers ,50335944 and 50344396. Expiration Date 04/11/2026
- Manufacturer
- Nestle Product Technology Center - Nestle Health Science
- Category
- Drug — Dietary Supplement
- Hazard
- mis-labeling
- formulation-mismatch
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Codes: 50335944
- 50344396
Distribution
Distributed in 35 states:
- AK
- AZ
- CA
- CO
- DE
- FL
- GA
- IA
- ID
- IL
- IN
- KS
- KY
- LA
- MA
- MD
- MI
- MN
- MO
- NC
- NH
- NJ
- NM
- NY
- OH
- OK
- OR
- PA
- SD
- TN
- TX
- VA
- WA
- WI
- WV
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27